$0.621
+0.016 (+2.53%)Al cierre
Noticias de CELZ
Eventos de CELZ
Creative Medical Reports Ultrasome Clinical Study Results
Creative Medical highlighted additional clinical and laboratory findings for Ultrasome, its investigational cell-free regenerative medicine platform, following a presentation at the annual meeting of experts in Cell and Gene Therapy held October 10 in Lima, Peru. The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants met study-defined response criteria. Importantly, the group's average reported pain score declined by approximately 65% from baseline to six months. The 65% figure refers to the reduction in the group-average pain score - not the percentage of patients reporting improvement. 93% patient response: 28 of 30 participants met the study-defined criteria for clinical improvement. Overall, 65% reduction in average pain score at six months post intervention. Overall, 52% reduction in average WOMAC score. Mean scores reflecting osteoarthritis-related pain, stiffness and physical limitations improved over six months. The group's average knee-related quality-of-life score increased by approximately 35 points.No serious adverse events were reported during six months of follow-up.
Creative Medical Files New Patent Application for Ultrasome
Creative Medical announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome, the company's proprietary cell-free regenerative medicine platform. The newly filed application builds upon Creative Medical's existing regenerative medicine intellectual property and seeks protection across multiple aspects of the Ultrasome platform, including proprietary product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches and therapeutic applications.
Creative Medical Completes Patient Enrollment for CELZ-201 Clinical Trial
Creative Medical announced that all patients have now been enrolled and treated across the company's entire FDA-cleared ADAPT clinical trial evaluating CELZ-201 / Olastrocel, including the original study cohorts and the FDA-cleared opioid expansion cohort.
Creative Medical Files to Sell 5.58M Shares of Common Stock
Creative Medical files to sell 5.58M shares of common stock for holders
Creative Medical Technology Enters Agreement for Immediate Exercise of 2,790,340 Warrants
Creative Medical Technology announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.5M, before deducting financial advisory fees. Roth Capital Partners is acting as the company's financial advisor for this transaction. In consideration for the immediate exercise of the existing warrants for cash, the company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of $1.60 per share upon the receipt of shareholder approval for a term of five years from the initial exercise date. The transaction is expected to close on June 30, 2026. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
Artículos relacionados
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.